Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2525 - Oral squamous cell carcinoma cells were sensitized to cetuximab by Eribulin via induction of the mesenchymal-to-epithelial transition.


11 Sep 2017


Poster display session


Cancer Biology


hiroko kitahara


Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361


H. kitahara, M. HIRAI, S. Kawashiri, H. Nakamura

Author affiliations

  • Oral And Maxillofacial Surgery, Kanazawa University Graduate School of Medical Science, 920-8641 - Kanazawa/JP


Abstract 2525


Inhibition of EGFR signalling has emerged as a new treatment strategy for oral squamous cell carcinoma (OSCC). Previously, we found that loss of EGFR expression in OSCC was associated with EMT, and might have functional implications with regard to resistance to cetuximab, a monoclonal anti-EGFR antibody. Eribulin (a microtubule inhibitor) reportedly renders breast cancer less aggressive, and less likely to metastasise, by triggering the mesenchymal-to-epithelial (MET) transition. Here, we evaluated whether eribulin-induced MET was associated with re-sensitization of resistant OSCC cell lines to cetuximab.


In vitro antiproliferative activities were determined in three human OSCC lines (OSC-20, OSC-19 and HOC313) treated with eribulin. These three human OSCC represented different EMT/MET states.


Interestingly, HOC313 cells (mesenchymal phenotype) were highly sensitive to eribulin in comparison with other cell lines, and significantly enhanced the anti-proliferative effect of cetuximab in response to the drug. Eribulin also underwent a MET-associated gene switch that resulted in high EGFR expression in HOC313 cells, and abrogated a TGF-β-induced EMT gene expression signature.


Eribulin-dependent sensitization of OSCC to cetuximab is likely due to induction of MET. Combination therapies based on eribulin and cetuximab have potential as a novel treatment regimen in OSCC.

Clinical trial identification

Legal entity responsible for the study

Kanazawa University




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.